Live Breaking News & Updates on Allogene Therapeutics Inc|Page 1

Stay updated with breaking news from Allogene therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Insider Selling: Allogene Therapeutics, Inc. (NASDAQ:ALLO) Director Sells 11,200 Shares of Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) Director Franz B. Humer sold 11,200 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $2.34, for a total value of $26,208.00. Following the completion of the sale, the director now owns 255,253 […] ....

Franzb Humer , Piper Sandler , Canada Life Assurance , Pricet Rowe Associates Inc , Allogene Therapeutics Company Profile , Allogene Therapeutics Inc , Susquehanna Fundamental Investments , Jpmorgan Chase Co , Securities Exchange Commission , Headlands Technologies , Mirae Asset Global Investments Co , Allogene Therapeutics , Get Free Report , Director Franz , Exchange Commission , Fundamental Investments , Mirae Asset Global Investments , Asset Global Investments , Allogene Therapeutics Daily ,

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Analysts

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month […] ....

Switzerland General , Arie Belldegrun , Piper Sandler , Jpmorgan Chase Co , Securities Exchange Commission , Royal Bank , Sg Americas Securities , Allogene Therapeutics Inc , Citigroup Inc , Swiss National Bank , Alps Advisors Inc , Allogene Therapeutics , Get Free Report , Director Arie Belldegrun , Exchange Commission , National Bank , Alps Advisors , Get Free , Allogene Therapeutics Daily ,

Allogene Therapeutics (NASDAQ:ALLO) Now Covered by Analysts at Piper Sandler

Piper Sandler initiated coverage on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a report published on Friday, Marketbeat reports. The brokerage issued an overweight rating and a $11.00 target price on the stock. ALLO has been the subject of several other research reports. Royal Bank of Canada reissued an outperform rating and issued […] ....

United States , Stifel Nicolaus , Piper Sandler , Arie Belldegrun , Victory Capital Management Inc , Harbor Capital Advisors Inc , Vontobel Holding Ltd , Allogene Therapeutics Inc , Royal Bank , Jpmorgan Chase Co , Principal Financial Group Inc , Securities Exchange Commission , Allogene Therapeutics , Free Report , Moderate Buy , Get Free Report , Director Arie Belldegrun , Exchange Commission , Capital Management , Financial Group , Capital Advisors , Arizona State Retirement System , State Retirement System , Allogene Therapeutics Daily ,

Analyst Ratings For Allogene Therapeutics - Allogene Therapeutics (NASDAQ:ALLO)

Analyst Ratings For Allogene Therapeutics - Allogene Therapeutics (NASDAQ:ALLO)
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Health Care , Allogene Therapeutics Inc , Allogene Therapeutics , Analyst Ratings , Therapeutics Inc , Revenue Trend , Examining Allogene Therapeutics , What Every Investor Should ,